Anthrax - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 154
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5A46C43DC2EN
Leaflet:

Download PDF Leaflet

Anthrax - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Anthrax - Pipeline Review, H2 2016’, provides an overview of the Anthrax pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Anthrax
  • The report reviews pipeline therapeutics for Anthrax by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anthrax therapeutics and enlists all their major and minor projects
  • The report assesses Anthrax therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anthrax
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anthrax
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Anthrax Overview
Therapeutics Development
Pipeline Products for Anthrax - Overview
Pipeline Products for Anthrax - Comparative Analysis
Anthrax - Therapeutics under Development by Companies
Anthrax - Therapeutics under Investigation by Universities/Institutes
Anthrax - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Anthrax - Products under Development by Companies
Anthrax - Products under Investigation by Universities/Institutes
Anthrax - Companies Involved in Therapeutics Development
Aduro BioTech, Inc.
Altimmune, Inc.
Aphios Corporation
Aradigm Corporation
AtralCipan
Cellceutix Corporation
ContraFect Corporation
Dynavax Technologies Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline Plc
Green Cross Corporation
Grifols, S.A.
Hawaii Biotech, Inc.
iBio, Inc.
Merck & Co., Inc.
Microbiotix, Inc.
NanoBio Corporation
PaxVax, Inc.
Pfenex Inc.
PharmAthene, Inc.
Planet Biotechnology Inc.
Protein Potential, LLC
ProThera Biologics, LLC.
Soligenix, Inc.
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
United Therapeutics Corporation
VLP Biotech, Inc.
Anthrax - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anthrax (virus like particles) vaccine - Drug Profile
anthrax + plague vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine 2 - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile
ARD-3100 - Drug Profile
AV-7909 - Drug Profile
CF-306 - Drug Profile
CF-307 - Drug Profile
CF-308 - Drug Profile
ciprofloxacin hydrochloride - Drug Profile
DPX-Anthrax - Drug Profile
DV-230 - Drug Profile
Epimerox - Drug Profile
GC-1109 - Drug Profile
GREANX - Drug Profile
Human Antibody Based Vaccines - Drug Profile
KKL-35 - Drug Profile
Marinus - Drug Profile
Monoclonal Antibody for Respiratory Anthrax - Drug Profile
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
PBI-220 - Drug Profile
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
PMX-0196 - Drug Profile
PMX-0243 - Drug Profile
PMX-225 - Drug Profile
PMX-231 - Drug Profile
PMX-255 - Drug Profile
PreviThrax - Drug Profile
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile
Px-563L - Drug Profile
Px-563L Second Generation - Drug Profile
raxibacumab - Drug Profile
RC-100b - Drug Profile
RiVax + SGX-204 - Drug Profile
Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile
Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile
Small Molecules for Anthrax - Drug Profile
Small Molecules for Bacterial Infections - Drug Profile
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
solithromycin - Drug Profile
TP-271 - Drug Profile
Anthrax - Dormant Projects
Anthrax - Discontinued Products
Anthrax - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Anthrax, H2 2016
Number of Products under Development for Anthrax - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Anthrax - Pipeline by Aduro BioTech, Inc., H2 2016
Anthrax - Pipeline by Altimmune, Inc., H2 2016
Anthrax - Pipeline by Aphios Corporation, H2 2016
Anthrax - Pipeline by Aradigm Corporation, H2 2016
Anthrax - Pipeline by AtralCipan, H2 2016
Anthrax - Pipeline by Cellceutix Corporation, H2 2016
Anthrax - Pipeline by ContraFect Corporation, H2 2016
Anthrax - Pipeline by Dynavax Technologies Corporation, H2 2016
Anthrax - Pipeline by Emergent BioSolutions Inc., H2 2016
Anthrax - Pipeline by GlaxoSmithKline Plc, H2 2016
Anthrax - Pipeline by Green Cross Corporation, H2 2016
Anthrax - Pipeline by Grifols, S.A., H2 2016
Anthrax - Pipeline by Hawaii Biotech, Inc., H2 2016
Anthrax - Pipeline by iBio, Inc., H2 2016
Anthrax - Pipeline by Merck & Co., Inc., H2 2016
Anthrax - Pipeline by Microbiotix, Inc., H2 2016
Anthrax - Pipeline by NanoBio Corporation, H2 2016
Anthrax - Pipeline by PaxVax, Inc., H2 2016
Anthrax - Pipeline by Pfenex Inc., H2 2016
Anthrax - Pipeline by PharmAthene, Inc., H2 2016
Anthrax - Pipeline by Planet Biotechnology Inc., H2 2016
Anthrax - Pipeline by Protein Potential, LLC, H2 2016
Anthrax - Pipeline by ProThera Biologics, LLC., H2 2016
Anthrax - Pipeline by Soligenix, Inc., H2 2016
Anthrax - Pipeline by Syntiron LLC, H2 2016
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
Anthrax - Pipeline by United Therapeutics Corporation, H2 2016
Anthrax - Pipeline by VLP Biotech, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Anthrax - Dormant Projects, H2 2016
Anthrax - Dormant Projects (Contd..1), H2 2016
Anthrax - Dormant Projects (Contd..2), H2 2016
Anthrax - Dormant Projects (Contd..3), H2 2016
Anthrax - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Anthrax, H2 2016
Number of Products under Development for Anthrax - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Aduro BioTech, Inc.
Altimmune, Inc.
Aphios Corporation
Aradigm Corporation
AtralCipan
Cellceutix Corporation
ContraFect Corporation
Dynavax Technologies Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline Plc
Green Cross Corporation
Grifols, S.A.
Hawaii Biotech, Inc.
iBio, Inc.
Merck & Co., Inc.
Microbiotix, Inc.
NanoBio Corporation
PaxVax, Inc.
Pfenex Inc.
PharmAthene, Inc.
Planet Biotechnology Inc.
Protein Potential, LLC
ProThera Biologics, LLC.
Soligenix, Inc.
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
United Therapeutics Corporation
VLP Biotech, Inc.
Skip to top


Anthrax - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 166 pages
Microbiotix, Inc. - Product Pipeline Review - 2016 US$ 1,275.00 Mar, 2016 · 52 pages
Hawaii Biotech, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Sep, 2015 · 24 pages
PaxVax - Product Pipeline Review - 2014 US$ 1,125.00 Sep, 2014 · 27 pages
Syntiron LLC - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 23 pages

Ask Your Question

Anthrax - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: